Objective-The aim of our study is to determine the cellular and molecular origin for the pericytes in infantile hemangioma (IH) and their functional role in the formation of pathological blood vessels. Methods and Results-Here we show that IH-derived stem cells (HemSCs) form pericyte-like cells. With in vitro studies, we demonstrate that HemSC-to-pericyte differentiation depends on direct contact with endothelial cells. JAGGED1 expressed ectopically in fibroblasts was sufficient to induce HemSCs to acquire a pericyte-like phenotype, indicating a critical role for JAGGED1. In vivo, we blocked pericyte differentiation with recombinant JAGGED1, and we observed reduced formation of blood vessels, with an evident lack of pericytes. Silencing JAGGED1 in the endothelial cells reduced blood vessel formation and resulted in a paucity of pericytes. Conclusion-Our data show that endothelial JAGGED1 controls HemSC-to-pericyte differentiation in a murine model of IH and suggests that pericytes have a fundamental role in formation of blood vessels in IH. (Arterioscler Thromb Vasc Biol. 2011;31:2181-2192.)
I nfantile hemangioma (IH), the most common tumor of infancy, is an important model for the study of pathological disruptions of human vascular development. IH is a lesion of disorganized vasculature that appears around the second week of life, grows over the course of 6 to 9 months, and involutes during childhood. [1] [2] [3] [4] We previously identified and isolated IH-derived stem cells (HemSCs) from proliferating IH surgical specimens. 5 HemSCs are stem cells based on (1) clonal expansion from a single cell in vitro, (2) multilineage differentiation ability, and (3) formation of functional hemangioma-like (GLUT1ϩ) 6 blood vessels in primary and secondary recipient mice. 7 In addition, the central role of HemSCs is supported by our study showing that corticosteroids, a standard treatment for IH, target the HemSCs by downregulating vascular endothelial growth factor (VEGF)-A expression. 8 IH blood vessels are surrounded by pericytes, 9, 10 but the cellular origin of these cells has not been investigated.
Here we show that clonally expanded HemSCs give rise to the pericyte/vascular smooth muscle cells, which for simplicity we will refer to as pericytes. The acquisition of the pericytic phenotype is dependent on cell contact with endothelial cells. Because of this, we investigated NOTCH ligands in pericytic differentiation. NOTCH signaling occurs through juxtacrine interactions and plays a crucial role in vascular and tumor development. [11] [12] [13] The NOTCH family comprises 4 receptors (NOTCH1 to NOTCH4) and the ligands, JAGGED (JAG1, JAG2) and Delta-like (DLL1, DLL3, and DLL4). 14, 15 We recently reported the expression of NOTCH receptors and ligands in tissue and cells from IH. 16 JAGGED1 is upregulated in IH-derived endothelial cells (HemECs), 16 and IH endothelium, 17 whereas only modest expression of the vascular tip-cell regulator Dll4 16, 18 has been reported in HemECs. 16 However, JAGGED1 signaling mechanisms in the pathogenesis of IH are still unknown.
Mutations in JAGGED1 cause the human disease Alagille syndrome. 19 Alagille syndrome patients develop intracranial vessel abnormalities, as well as congenital cardiac disease, 20, 21 cerebral aneurysms, and coarctations. 20 Jagged1 knockout mice die between embryonic days 10.5 and 11.5 with defects in the yolk sac and embryonic vasculature. 22 Endothelial-specific deletion of Jagged1 results in deficit in smooth muscle differentiation, a phenotype similar to that of Jagged1 total knockout and Jagged1 mutants. 18, 23 We report here the direct involvement of JAGGED1 in the HemSC-to-pericyte differentiation, suggesting an important role for pericytes in the formation of IH blood vessels. These results provide novel insight into mechanisms of human postnatal vasculogenesis.
Methods

Cell Isolation and Culture
Specimens of IH were obtained under a protocol approved by the Committee on Clinical Investigation, Children's Hospital Boston. The clinical diagnosis was confirmed in the Department of Pathology, Children's Hospital Boston. Informed consent was obtained, according to the Declaration of Helsinki. Single-cell suspensions were prepared from proliferating phase IH specimens, and HemSCs were selected and expanded as described. 7 Briefly, HemSCs were selected using anti-CD133-coated magnetic beads (Miltenyi Biotec). CD133-selected cells were cultured on fibronectin-coated (1 g/cm 2 ) plates with EBM-2 (CC-3156, Cambrex). EBM-2 was supplemented with 20% fetal bovine serum, endothelial growth medium-2 SingleQuot (CC-4176; Cambrex). Hereafter, this supplemented medium is called EBM-2/20% fetal bovine serum. Hemangioma-derived endothelial cells (HemECs) and human umbilical cord blood endothelial progenitor cells (cbEPCs) were isolated as described. 24 cbEPCs were shown to form the endothelial lining of blood vessels when injected in combination with smooth muscle cells or bone marrow-derived mesenchymal progenitor cells, in Matrigel, subcutaneously in mice. 25, 26 Human dermal fibroblasts (HDFs) were purchased from ATCC. JAGGED1 expressing HDFs were produced by transfecting (Fugene HD, Roche) the cells with JAGGED1 vector (Origene); selection was done with G418 (Sigma-Aldrich). Short hairpin RNA (shRNA) lentiviral particles for JAGGED1 targeting (NM_00214) and nontargeting shRNA (control) were used to infect cbEPCs (Sigma-Mission). cbEPCs with stable expression of JAGGED1 shRNA were subjected to puromycin selection, according to the manufacturer's instructions. The pool used for in vivo experiments was selected after testing 5 different shRNA sequences for silencing efficacy.
Coculture Differentiation Protocol
The in vitro pericytic differentiation was performed by seeding HemSCs together with cbEPCs at a ratio of 1:1 and a total density of 10 4 cells/cm 2 on fibronectin-coated plates in EBM-2/20% fetal bovine serum. To inhibit the HemSC pericytic differentiation, we used recombinant human Fc-JAGGED1 and Fc-DLL4, and mouse anti-JAGGED1 (R&D Systems). Inhibitors were added 4 hours after cell plating, and medium/inhibitors was replaced every other day.
For detailed methods, see the supplemental material, available online at http://atvb.ahajournals.org.
Results
IH Blood Vessels Contain Pericytes
Blood vessels that emerge during the proliferating phase of IH are encircled by perivascular cells, which are defined in the literature as pericytes expressing ␣-smooth muscle actin (␣-SMA)ϩ. 9, 10 Our results show that the majority of these perivascular cells express neural glial antigen-2, plateletderived growth factor receptor (PDGFR)␤, calponin I, ␣-SMA, and smooth muscle myosin heavy chain (smMHC) (Figure 1a ). To study the perivascular contribution in blood vessels, we quantified mRNA expression of pericyte markers and normalized to the endothelial content (CD31) of the IH tissue. We expected a major role for the pericytes in the maturation (ie, involuting phase) of IH blood vessels. Instead, pericyte/smooth muscle markers were expressed in both proliferating and involuting phases, and we did not detect statistically significant differences between the 2 groups ( Figure 1b and Supplemental Figure Ia ). The localization of these markers indicates that perivascular cells surrounding IH vessels have features of pericytes and smooth muscle cells. For simplicity, and because the perivascular cells in IH are typically a single layer, we refer to them as pericytes.
HemSCs Differentiate Into Pericytes When Injected Into Mice
To assess whether pericytes are present in the HemSC-derived blood vessels in our murine model of IH, HemSCs were suspended in Matrigel and injected into nude mice. 7 After 7 days, Matrigel explants showed calponinϩ cells surrounding human CD31ϩ blood vessels. (Figure 1c , left). Pericytes, in the murine model of IH, are characterized by coexpression of ␣-SMA and calponin (Figure 1c , right). To further test whether the ␣-SMAϩ pericytes arose from HemSCs, we injected green fluorescent protein (GFP)-labeled HemSCs (GFP-HemSCs). The presence of ␣-SMAϩ/GFPϩ pericytes confirmed their HemSC origin ( Figure 1d ). We previously reported that Hem-SCs can differentiate into endothelial cells. 7 To verify that pericytes and endothelial cells are derived from the same progenitor cell, we prepared 3 single-cell-derived clonal populations of GFP-HemSCs derived from 2 different IH samples (Supplemental Figure Ib 
HemSCs Differentiate Into Pericytes When Combined With cbEPCs
In previous studies, we described a model to bioengineer human blood vessels using bone marrow-derived mesenchymal progenitor cells and cbEPCs. In this model, bone marrow-derived mesenchymal progenitor cells differentiate into ␣-SMAϩ pericytes, whereas cbEPCs form the endothelium. 25 To augment the HemSC-to-pericyte differentiation, we implanted HemSCs together with cbEPCs into mice. This resulted in a blood vessel density 4-to 5-fold higher than HemSCs implanted alone. 8 GFP-HemSCϩcbEPC produced vessels surrounded by GFPϩ/␣-SMAϩ cells (Figure 2a ), providing direct evidence that GFP-HemSCs became pericytes. Furthermore, 3 of 3 GFP-HemSC clonal populations differentiated into ␣-SMAϩ pericytes when injected with cbEPCs (Supplemental Figure IIa) . Quantitative analysis showed that 82% (82Ϯ4) of blood vessels had ␣-SMAϩ pericytes and 33% (33Ϯ2.1) had HemSC-derived pericytes (GFPϩ/␣-SMAϩ). Of the total GFPϩ blood vessels, 73% (33/45) coexpressed ␣-SMA (Figure 2a , bottom). We hypothesize that the remaining 27% of the GFPϩ vessels are composed of GFP-HemSCs that underwent endothelial differentiation or remained undifferentiated. To confirm that cbEPCs contributed exclusively to the endothelial population, GFP-cbEPCs were coimplanted with unlabeled-HemSCs. No colocalization of eGFP with ␣-SMA was seen around blood vessels, confirming that cbEPCs do not differentiate into pericytes (Figure 2b) .
To examine the contribution of murine cells to the pericytic population, we implanted unlabeled-HemSCsϩcbEPCs into GFP-SCID mice 27 (Figure 2c ), as well HemSCs alone ( Figure  2d ). In both models, we observed a mosaic of vessels with murine-and HemSC-derived ␣-SMAϩ pericytes. When HemSCϩcbEPCs were injected into GFP-SCID mice, ␣-SMAϩ pericytes were derived mostly from the HemSCs (Figure 2c , bottom). When HemSCs alone were injected into GFP-SCID mice, no statistical difference was seen between host (murine) and HemSC (human) contribution to the ␣-SMAϩ pericytes (Figure 2d , bottom). This shows that, when in contact with cbEPCs, HemSCs prefer to take on the pericytic phenotype. Pericytes in the murine model of IH also stained for calponin, most of erythrocytes-filled-blood vessels were surrounded by calponinϩ cells, and calponin staining signal overlapped with ␣-SMA (Supplemental Figure IIb) .
HemSCs Cocultured With cbEPCs Differentiate Into Pericytes
Data in Figure 2 showed that HemSCs combined with cbEPCs resulted in HemSC-to-(␣-SMAϩ) pericyte differentiation. This prompted us to analyze the role of cbEPC when cocultured with HemSCs. After 10 days, anti-␣-SMA and -smMHC identified pericyte-like cells (Figure 3a , left). HemSCs and cbEPCs cultured alone did not express pericyte/smooth muscle cell markers (Supplemental Figure IIIa) . To confirm that HemSCs differentiate into pericyte-like cells, we cocultured cbEPCs with GFP-HemSCs and showed that all of the ␣-SMAϩ and smMHCϩ cells were derived from the GFP-HemSCs ( Figure   3a , right); and GFP-HemSCs cultured alone did not express ␣-SMA or smMHC (Supplemental Figure IIIb) . Calponin-1 and sm22␣ are markers of pericyte-like cells. 28, 29 HemSCϩcbEPC cocultures showed significant induction of calponin-1, sm22␣, ␣-SMA protein (Figure 3b ), and calponin-1 and smMHC mRNA (PϽ0.001) ( Figure 3c ) compared with HemSCs alone. The expression of calponin-1, smMHC, and ␣-SMA gradually increased from day 3 to day 10 ( Figure 3c ). In addition, hemangioma-derived endothelial cells (HemECs) also caused HemSC-to-pericyte differentiation (Supplemental Figure IIIc) .
To further confirm that the HemSCs acquired a pericytic phenotype, we cocultured HemSCϩcbEPC for 5 days and, after trypsinization, selected the cells based on the expression of CD31 (CD31ϩ indicates endothelial cells), or lack of CD31 (CD31Ϫ indicates HemSCs and HemSC-derived pericytes). Real-time analysis showed that CD31Ϫ cells from coculture significantly upregulated PDGFR␤ (Pϭ0.004) and neural glial antigen-2 (Pϭ0.004), and CD31 expression was not detected (Figure 3d ).
We next wanted to test the HemSC-derived pericytes for contractility to assess the specific acquisition of pericyte/ smooth muscle cell function. GFP-HemSCs were cultured with cbEPCs to obtain differentiation, and after 10 days the cbEPCs were removed with CD31 magnetic beads. The CD31Ϫ cells were assessed for contractility on a siliconbased substrata. CD31Ϫ cells obtained from the coculture showed almost a 3-fold increase in the capacity to form wrinkles in the silicon, compared with CD31Ϫ cells from GFP-HemSCs cultured alone (Figure 3e ). This indicates that the HemSC-derived pericytes acquired expression of pericyte/smooth muscle markers that functionally correlate with contractile force.
Next, to assess that each single HemSC has the ability to differentiate into a pericyte, we used single-cell-derived HemSC clones. 7 Six of 6 HemSC clones tested, cocultured with cbEPCs, showed induction of ␣-SMA and smMHC (Supplemental Figure IIId) and calponin-1 (Supplemental Figure IIIe) . These results exclude the possibility that mixed populations of unipotential cells were responsible for the pericyte-like phenotype.
Direct and Continuous HemSC-cbEPC Contact Is Required for Pericyte Differentiation
The endothelial component in the coculture was crucial in the HemSC-to-pericyte differentiation. We next tested whether HemSC-derived pericytes could maintain their phenotype if endothelial cells were removed. We used GFP-HemSCs because of their puromycin resistance induced by lentiviral insertion of a vector containing GFP and the puromycinresistance genes. GFP-HemSCsϩcbEPCs were cocultured for 10 days to obtain ␣-SMA/smMHC expressing cells; after replating, the cells were treated with puromycin ( Figure 4a ). As expected, cbEPCs died after 2 days, confirmed by the absence of von Willebrand factor staining. The surviving cells (puromycin-resistant GFP-HemSCs) were cultured for up to 20 days. smMHC expression became undetectable after 15 days. ␣-SMA expression was retained until day 20, but cellular morphology, beginning at day 15, reverted to a spindle shape (Figure 4b ). Results were confirmed by gradual decrease of calponin-1 (Figure 4c ) and calponin-1/tubulin (Figure 4d Figure IVc) . This experiment indicates that continuous physical contact with endothelial cells is needed for the GFP-HemSCs to maintain the pericyte phenotype.
To test whether HemSC differentiation could occur without direct cellular contact with cbEPCs, we cultured HemSCs alone on the bottom well and cbEPCs or HemSCsϩcbEPCs on the top well of a 0.4-m-pore Transwell. HemSCs did not express smMHC under these conditions ( Supplemental Figure IVd) . We tested specific factors reported to induce smooth muscle differentiation (transforming growth factor-␤1, platelet-derived growth factor-BB, type IV collagencoated wells). 30 -32 After 10 days, smMHC was not detected, and only rare ␣-SMAϩ cells were seen (Supplemental Figure  IVe) . Without direct endothelial cell contact, the HemSCs were unable to differentiate toward the pericyte/smooth muscle phenotype under the culture conditions tested.
JAGGED1 Is Required for HemSC-to-Pericyte Differentiation and Blood Vessel Formation
We and others recently reported high JAGGED1 expression in IH endothelium. 16, 17 We further confirmed these findings here, as shown by the high JAGGED1 mRNA and protein expression in HemECs (Supplemental FigureVa) and JAGGED1 in endothelium of a proliferating IH specimen ( Supplemental Fig-ureVb) . We used different approaches to explore the role of the endothelial JAGGED1 in the HemSC-to-pericyte differentiation. The first was to inhibit membrane-bound JAGGED1 binding to its ligand/s by adding recombinant human (rh) Fc-JAGGED1 (Fc-JAGGED1) to the HemSCϩcbEPC cocultures. Fc-JAGGED1 (0.1 g/mL) limited HemSC-to-pericyte differentiation as indicated by reduced calponin-1 and smMHC expression, compared with human recombinant Fc-domain ( Figure 5a ).
On NOTCH receptor signaling, the intracellular domain of NOTCH is cleaved by ␥-secretases and is translocated to the nucleus where it associates with the RBP-Jk proteins to induce transcription of the basic helix-loop-helix genes HES and HEY, which are the most prominent NOTCH effector molecules. 33 We assessed NOTCH ligand-induced signaling by measuring HES and HEY. Treatment with Fc-JAGGED1 significantly decreased (PϽ0.05) HES1 and HEYL mRNA expression ( Figure 5a ). Fc-JAGGED1 also prevented calponin-1 and sm22␣ protein upregulation in HemSCs purified from the cocultures (Figure 5b) . Additionally, the number of ␣-SMAϩ cells in cocultures treated with Fc-JAGGED1 showed an 80% reduction compared with the Fc-domain control (Figure 5c ). In vivo, Fc-JAGGED1 affected vessel integrity, suggesting a disruption in the perivascular coverage (Figure 5d ). Fc-JAGGED1 significantly (PϽ0.05) reduced the total microvessel density (MVD) and the human CD31ϩ MVD (Figure 5d ).
The NOTCH ligand DDL4 was reported to have a role in the pericyte/smooth muscle differentiation of bone marrow cells and in the vessel maturation. 34, 35 Therefore, we investigated the effect of DDL4 blockade in the HemSC-to-pericyte differentiation. HemSCϩcbEPC and HemSCϩHemEC cocultures were treated with rhJAGGED1, rhDLL4, or a combination of both. Results showed that DLL4 blockade did not inhibit calponin, ␣-SMA, or sm22␣ expression, and we did not detect any additional reduction in calponin, ␣-SMA, or sm22␣ when rhDLL4 was added with rhJAGGED1 (Supplemental Figure Vc) . These results are in line with our previous report on modest levels of DLL4 in HemEC compared with human dermal microvascular EC, and they suggest that, as DLL4 expression is low in HemEC, DLL4 blockade may not affect HemEC-induced HemSC-to-pericyte differentiation.
To confirm that blockade of JAGGED1 signaling inhibits HemSC-to-pericyte differentiation, we treated cbEPCϩ HemSC cocultures with anti-JAGGED1 antibody. Results showed significant decreases (PϽ0.05) in calponin-1, smMHC, and HES1 and HEYL mRNA compared with cocultures treated with control mouse IgG (Supplemental Figure Vd) .
Fc-JAGGED1 blocked rather than induced pericytic differentiation, as reported in the literature 36, 37 ; therefore, we tested whether cell-bound JAGGED1 was sufficient to stimulate differentiation. We transfected HDFs with an expression plasmid for JAGGED1 ( Figure 5e ), and cocultured them with HemSCs. After 5 days, HemSCϩJAGGED1-HDF cocultures exhibited increased (PϽ0.05) mRNA expression of calponin-1, smMHC, NOTCH3, HES1, HEYL, neural glial antigen-2, PDGFR␤, ␣-SMA, and sm22a compared with HemSCϩempty vector-HDF cocultures (Figure 5f ). Therefore, JAGGED1 on a nonendothelial membrane was sufficient to stimulate HemSCs to differentiate toward a pericytelike phenotype in vitro.
To test whether JAGGED1 is necessary in the HemSC-topericyte differentiation, we downregulated JAGGED1 in cbEPCs using shRNA-mediated silencing. Two cbEPCs pools with downregulated JAGGED1 (shJAGGED1-pool1 and shJAGGED1-pool2) (Figure 6a ), were combined with HemSCs and coinjected into mice. The shJAGGED1 cbEPCs showed decreased MVD and human-derived CD31ϩ MVD compared with the control nontargeting shRNA (Figure 6b and Supplemental Figure VIa) that correlated with the level of decreased JAGGED1. To assess pericytic coverage of the vessels, sections were immunostained for human CD31 in combination with anti-␣-SMA antibody. Specificity of antihuman CD31 is shown in Supplemental Figure VIb . Quantification of the human CD31ϩ vessels with ␣-SMAϩ pericytes versus murine vessels (human CD31Ϫ) with ␣-SMAϩ pericytes revealed that JAGGED1 silencing affected only the pericyte coverage of the human-CD31ϩ vessels ( Figure  6c ). These results confirmed that JAGGED1 in cbEPCs is responsible for the HemSC-derived vasculogenesis. In addition, we tested Matrigel explants for presence of GFP-HemSC-derived ␣-SMAϩ pericytes. Explants of GFP-HemSCϩshJAGGED1cbEPCs exhibited a significant reduction (PՅ0.004) of GFPϩ/␣-SMAϩ cells (compared with control, nontransfected cells, and nontargeting shRNAtreated cells). (Representative pictures are shown in Figure 6d and quantification in Figure 6e ).
Discussion
In this study, we showed that HemSCs can differentiate into pericytes in vitro and in vivo, suggesting that pericytes in IH originate from HemSCs. Furthermore, we present the first evidence of a functional role for JAGGED1 in the pericytic differentiation of HemSCs, suggesting that JAGGED1 may be involved in the pathogenesis of IH. Because we showed previously that HemSCs can differentiate into endothelial cells, the HemSC-to-pericyte differentiative capability provides, for the first time to our knowledge, evidence for a human postnatal vascular progenitor cell.
For many years, IH has been thought to originate from aberrant endothelium and excessive angiogenesis. 38, 39 However, attempts to create an IH model by injecting HemECs into immune-deficient mice have failed. 7 Our HemSC-IH model represents an important advance to previously published models 40, 41 because the patient-derived HemSCs form hemangioma-like GLUT1ϩ 6 vessels within 7 days and adipocytes by 8 weeks, 4,7 thereby recapitulating important events in the IH life-cycle. HemSCs have also been shown to be the cellular target of corticosteroids, 8 supporting the critical role of HemSCs during the growth of IH. We propose that IH arises by HemSC-driven vasculogenesis, defined as the de novo formation of blood vessels from stem/progenitor cells.
IH vessels are surrounded by closely associated perivascular cells that express markers of pericytes (neural glial antigen-2, PDGFR-␤, and ␣-SMA) and smooth muscle cells (␣-SMA, calponin and smMHC) (Figure 1a and 1b) . In contrast, tumor vessels have perivascular cells that are often loosely associated or appear detached. [42] [43] [44] [45] Tumor blood vessels expand through an angiogenic program in which VEGF-A negatively regulates perivascular coverage preventing tumor endothelial cell maturation. 46 In contrast, we show here that pericytes in IH are critical because inhibition of HemSC-to-pericyte differentiation severely compromised blood vessel assembly in our IH murine model (Figures 5d  and 6 ).
Embryonic vascular progenitor cells have been shown to differentiate into endothelial and pericytic phenotypes in response to VEGF-A and transforming growth factor-␤ or platelet-derived growth factor-BB. 30 -32 In contrast, cellular contact with an endothelial cell, cbEPC or HemEC, was needed for HemSC-to-pericyte differentiation (Figures 3 and  4 ). In addition, JAGGED1-expressing fibroblasts were sufficient to induce the HemSCs to acquire a pericyte-like phenotype (Figure 5e and 5f ). Furthermore, soluble recombinant Fc-JAGGED1 thwarted differentiation of the HemSCs (Figure 5a to 5c) and inhibited blood vessel formation in the IH murine model (Figure 5d ). This was perhaps due to disruption of juxtacrine interactions between endothelial JAGGED1 and a NOTCH receptor on HemSCs. 16 Silencing of JAGGED1 in the cbEPCs resulted in a dose-dependent decrease in the vascular density and pericytes in the IH murine model ( Figure 6 ). Endothelial JAGGED1 is crucial for vascular smooth muscle development. 23, 47 Furthermore, angiogenic sprouting in the retina is inhibited in the endothelial Jag1 loss of function model. 18 In this model, the authors reported a lack of ␣-SMAϩ smooth muscle cells on developing arteries, but the pericyte coating seemed unaffected. Our results may differ because IH blood vessels form through a vasculogenic process, with angiogenic sprouting as secondary event.
We also tested inhibitors of receptor-ligand pathways that have been implicated in vascular development, including ␥-secretase inhibitors to prevent NOTCH juxtacrine signaling. Recombinant Tie2, an ERK inhibitor (U0126), and a PDGFR␤ inhibitor (AG1295) did not prevent HemSC-topericyte differentiation in the coculture assay (Supplemental Figure VII) , but 2 different ␥-secretase blockers (N-[N-(3,5difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester and Compound E) were inhibitory (Supplemental Figure  VIII) . DAPT was tested in the IH murine model and resulted in reduced MVD and reduced ␣-SMAϩ cells in proximity to blood vessels. Importantly, DAPT had little effect on proliferation or viability of HemSCs and cbEPCs in vitro. This supplemental data supports the idea that JAGGED1 is exerting an effect on NOTCH signaling.
In summary, our study demonstrates that HemSCs differentiate into pericytes as well as endothelial cells and are thus akin to a vascular progenitor cell. We speculate that the first event of IH vasculogenesis is the differentiation of the HemSCs into HemECs. HemECs in turn induce neighboring HemSCs to become pericytes, thereby initiating a feedforward mechanism for vascular assembly and further growth. Recruitment of circulating endothelial cells, through VEGF-A and matrix metalloproteinase-9, into the hemangioma could further contribute to the vasculogenesis 48, 49 and would diminish the need for HemSC-to-endothelial differentiation, enabling them to differentiate into pericytes.
VEGF-A is highly expressed in HemSCs and is required for the HemSC-derived blood vessel formation in the IH murine model. 8 VEGF-A plays a positive role in angiogenesis in concert with NOTCH signaling 50, 51 ; furthermore, authors have reported VEGF-A as a negative regulator of pericyte and vascular smooth muscle cells recruitment. 46 In contrast, pericytes are prevalent in the proliferating phase of IH 8 despite high levels of VEGF-A (Figure 1a and 1b) , Furthermore, preliminary data showed that when HemSCs and cbEPCs were cocultured, VEGF-A was upregulated and that DAPT inhibited this upregulation. We thereby speculate that in our model, VEGF-A expression can also be regulated downstream of NOTCH signaling.
